Megan Baldwin, PhD
CEO & Managing Director
Megan Baldwin, PhD is CEO and Managing Director of Opthea Limited with over 20 years of experience in angiogenesis and therapeutic strategies for cancer and ophthalmic indications. Dr Baldwin joined Opthea in 2008, and prior to that was employed at Genentech (now Roche), the world leader in the field of angiogenesis-based therapies for cancer and other diseases. Her experience included several years as a researcher in the angiogenesis group before moving to Genentech’s commercial division in the market planning department. Dr Baldwin holds a PhD in Medicine from the University of Melbourne, having conducted her doctoral studies at the Ludwig Institute for Cancer Research on the biology of VEGF-C/D, is a member of the Australian Institute of Company Directors and a director of Ausbiotech.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.